94 results about "Nasal administration" patented technology

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

The invention provides application of tea extracellular vesicles in preparation of drugs for relieving or treating allergic respiratory diseases, and belongs to the technical field of extracellular vesicles. The invention provides application of tea extracellular vesicles in preparation of drugs for relieving or treating allergic respiratory diseases. The tea extracellular vesicles are proved to be capable of remarkably improving related symptoms of allergic respiratory diseases including allergic rhinitis, have good anti-inflammatory and immunoregulation effects, and have the application potential of being used as natural active ingredients for preparing drugs or nasal delivery preparations for treating the allergic respiratory diseases. Compared with existing hormone drugs, the tea extracellular vesicles have the advantages of being natural in source, high in safety, low in side effect and the like; moreover, the extracellular vesicles have nanoscale particle sizes, good mucous membrane permeability and bioavailability, can improve the curative effect, and are suitable for long-term intervention.

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

The present disclosure provides a nasal delivery device with a device body that includes a trigger end and an outlet end. The nasal delivery device also includes a trigger assembly coupled to the trigger end of the device body, a drug container supported by the device body, and a spring-loaded activator assembly supported by the device body and disposed between the trigger assembly and the drug container.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

1. The name of the design product: single dose nasal administration device. 2. The use of the design product: the design is mainly used in single dose nasal inhalation administration device. 3. The design points of the design product: in the design 1 perspective view. 4. The picture or photo that best indicates the design points: design 1 perspective view. 5. Design 1 is designated as the basic design.

The invention belongs to the technical field of pharmaceutical preparations, and provides a novel solution type nasal administration composition of quetiapine. In the provided composition, quetiapine is completely dissolved in the composition in the form of a solution, and is administered via the nose. The quetiapine solution type nasal preparation provided by the invention has especially useful pharmacokinetic and pharmacodynamic characteristics compared with oral dosage forms on the market. Compared with other disclosed nasal nano-emulsion forms, the nasal nano-emulsion still has surprising pharmacokinetic and pharmacodynamic characteristics, shows good clinical application prospects, and is expected to meet unsatisfied clinical requirements. On the basis, the invention also provides a further improved technical scheme of high saturated dissolution concentration and a further improved technical scheme of good chemical stability for preparing the quetiapine solution type nasal preparation.

The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.

A nasal pharmaceutical composition comprising a porous excipient and an active agent, wherein the active agent is loaded onto a surface of the porous excipient located within pores of the porous excipient, wherein the porous excipient is an inorganic porous material selected from colloidal silicon dioxide, mesoporous silica, microporous silica and macroporous silica, and wherein the loaded porous excipient is dispersed in a gel, the gel comprising a vehicle comprising an oil or a mixture of oils, and wherein the composition is designed for nasal administration.

1. The name of the design product: nasal cavity administration atomization device (without dust cover). 2. The use of the design product: the design product is used to spray the atomized medicine to the nasal cavity olfactory region. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 2.

The present application relates to the technical field of nasal administration, and more particularly to an ultrasound-enhanced olfactory mucosa brain-targeted infusion probe, system and method, wherein the probe comprises a probe catheter, an ultrasound activation module capable of enhancing the permeability of the olfactory mucosa of a patient, and a fit degree module capable of obtaining the size of the fit between the probe catheter and the lateral wall of the nasal cavity of the patient, the ultrasound activation module and the fit degree module are both installed on the lateral wall of the probe catheter, the ultrasound activation module and the fit degree module are connected with a control module through a wire bundle arranged on the inner lateral wall of the probe catheter, and the administration channel in the lumen of the probe catheter is in communication with the outside of the probe catheter through an administration port. The scheme of the present application can obtain the fit between the probe catheter and the lateral wall of the nasal cavity after the probe catheter is inserted into the nasal cavity, so as to facilitate the doctor to timely adjust the position of the probe catheter when the fit does not meet the working conditions of the probe catheter, and successfully fit the probe catheter to the specified position of the lateral wall of the nasal cavity.

A discharge head for nasal application of liquid from a pressure reservoir (110) is known. In order to be able to produce such a discharge head in a cost-effective manner, some measures are proposed. In particular, for this purpose, a discharge head (10) is proposed which has a base unit (20) with a coupling device (24), by means of which the discharge head (10) can be fastened to a pressure reservoir (110). The discharge head (10) has an actuation unit (50) with an elongate nasal applicator (60) extending along an applicator axis (4) and an actuation surface (70), and which is mounted on a base unit (20) in a pivotable manner about a pivot axis (6) by means of a hinge device (30, 90), such that for the purpose of opening an outlet valve (112) of a pressure reservoir (110), the actuation surface (70) is attached to the outlet valve (112) of the pressure reservoir (110). The actuation unit (50) can be pressed down in a pivot actuation direction. In particular, the components (22, 52) of the discharge head are produced by means of an injection mould that can be separated along an axis.

A plug (1) for insertion into the nose or ear of a subject, comprising: a body (10) adapted to fit into a nostril (2) or ear canal (3) of the subject and a tubular member (20) with a collar (25) disposed substantially inside the body. The plug is adapted to receive a tip of a syringe (30) for injection of a fluid therapeutic agent through the tubular member for nasal administration or administration to the ear. A kit comprising the plug and a syringe, as well as a method for administering a fluid therapeutic agent to a subject using the plug are also disclosed.

The present disclosure relates to compositions for the restoration of porosome faction, comprising isolated porosome complexes that include a functional CFTR protein and a pharmaceutically acceptable excipient. These compositions are specifically formulated for inhaled or nasal administration, enabling delivery of the functional porosome complexes directly to the airway epithelium. By restoring the presence of functional CFTR within the porosome complex at the plasma membrane, the disclosed compositions address the underlying secretory defect in cystic fibrosis and provide a novel therapeutic approach for patients affected by this disease.

The invention relates to a device for the nasal dispensing of a fluid or powdered product, the device comprising a dispensing head (10) that is provided with a dispensing opening (11) and is suitable for being at least partially inserted into a nostril during actuation, the dispensing head (10) being mounted on a reservoir (30) containing the fluid or powdered product to be dispensed, a dispensing member (20) being provided to dispense the product contained in the reservoir (30) in a dosed manner, the device comprising an end piece (40) arranged around the dispensing head (10) and comprising a bearing surface (41) which, in use, is designed to rest on the entrance of a nostril, and a finger-rest surface (45) for accommodating the fingers of a user when the device is being used, the finger-rest surface (45) curving upward, so as to form an upwardly curved cylindrical section that extends radially on either side of the dispensing head (10).

The invention discloses a lipophilic modified nucleic acid medicine composition and application thereof, the lipophilic modification is saturated or unsaturated C4-C30 alkyl, the composition comprises an absorption enhancer, and the method is that the lipophilic modified nucleic acid medicine is delivered to the brain through the nasal mucosa. Nucleic acid drugs are transmitted into the olfactory bulb region through a neural pathway, namely, cross-olfactory mucosa, bypass BBB and directly enter the brain, the drug concentration content of the olfactory bulb is far higher than that of other tissues of the brain, and the tissues except the olfactory bulb are uniformly distributed, so that the olfactory bulb can be used as a drug reservoir and gradually and slowly spread to the other tissues of the brain; the long-time drug effect can be maintained by one-time drug administration, so that the drug administration frequency can be reduced. Compared with intrathecal injection, by adopting the composition disclosed by the invention for nasal administration and using 1 / 2 of intrathecal administration dosage, the same intrathecal steady-state distribution as intrathecal distribution can be achieved, so that the method disclosed by the invention is safer, noninvasive and efficient.

The present invention concerns novel use of adrenaline for improving the treatment of shocks, comprising the intra-nasal administration of compositions of adrenaline.

1. The name of the design product: spray pump (without cap). 2. The use of the design product: the design product is used for the medicine nasal administration device. 3. The design points of the design product: in shape. 4. The picture or photo that can best show the design points: perspective view.

The application discloses a passive micro-fluidic liquid slow-release system and a nasal cavity drug delivery device, which comprises a micro-fluidic liquid storage bin, a multi-stage gradient flow resistance channel network, a slow-release unit and an air inlet and outlet balance assembly. The system makes the equivalent diameter of the micro-channel gradually decrease along the flow direction, concentrates the flow resistance on the end micro-hole, shields the liquid level fluctuation at the front end, and realizes passive constant pressure release. In view of the problems of liquid injection and start, independent air inlet and outlet micro-channels and a detachable elastic gas storage bin are introduced, air is discharged and liquid is sucked under negative pressure during liquid injection, the gas storage bin is pressed to generate a pulse to break a disposable micro-fluidic valve during start, and the air pressure is balanced through the air inlet channel during the release period to prevent vacuum deadlock. Combined with the continuous conical transition and the end biomimetic capillary groove liquid locking design, the application completely gets rid of the constraint of external power, and is suitable for portable nasal cavity essential oil slow-release and clinical micro-dosage.

The present invention relates to a pharmaceutical composition comprising ramelteon and a nasal administration formulation. The pharmaceutical composition comprises ramelteon and polyethylene glycol. The pharmaceutical composition of the present invention has high stability and can be used to prepare a pharmaceutical formulation that meets the specifications for nasal administration formulations. Compared with oral tablets, the pharmaceutical composition of the present invention features improved bioavailability of ramelteon and a targeted concentration in brain tissue.

The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof that inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Sustained-release oral pharmaceutical compositions comprising the pharmaceutical composition are described, as well as sustained-release injectable pharmaceutical compositions comprising the pharmaceutical composition.The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal administration comprising the pharmaceutical composition. Also described are: methods for evaluating the efficacy of the pharmaceutical composition; methods for evaluating the inhibitory or partial inhibitory activity of the pharmaceutical composition; methods for treating, alleviating, or preventing a condition or disease comprising administering a therapeutically effective amount of the pharmaceutical composition to a subject; and the use of the pharmaceutical composition for manufacturing a pharmaceutical dosage form for the treatment of a disease.

A discharge head for the nasal application of pharmaceutical liquid from a pressure reservoir which has an outlet valve with a valve connector, to which force can be applied counter to a spring force in order to open the outlet valve. The discharge head has a nasal applicator which extends outward from an actuating surface and at the end of which a discharge opening is provided. The discharge opening is connected in a fluid-communicating manner to a hollow tube through an applicator channel of the nasal applicator for connection to the pressure reservoir. The nasal applicator has an inner component connected integrally to the actuating surface and an outer component separate from the inner component and attached to the inner component in a surrounding manner. The discharge opening is provided in the outer component, and the outer component and the inner component together bound the applicator channel.

Provided herein are compositions and methods for treating spinal cord injury using nasal administration of anti-CD3 antibodies, e.g., foralumab.

The present application relates to the technical field of neuropharmacology and psychiatry, and discloses a nasal drug composition, which comprises a therapeutically effective dose of a 5-HT1D receptor antagonist or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable cyclodextrin or a derivative thereof; the composition is a nasal preparation, and after nasal administration, the elimination half-life of the 5-HT1D receptor antagonist in brain tissue is longer than that in plasma, or the 5-HT1D receptor antagonist is preferentially retained in brain tissue. The present application combines the 5-HT1D receptor antagonist, the specific cyclodextrin inclusion technology and the nasal administration route, only makes the poorly soluble CNI3176 into a high-concentration (such as 1 mg / mL) clear solution, significantly improves the physical and chemical stability of the preparation, and enables the drug to reach the brain target in a few minutes (Tmax≤0.1 h), thereby providing a new type of anti-anxiety treatment solution which is rapid in effect, significant in curative effect, low in side effect risk and possible to avoid tolerance.

The invention provides a preparation method of a traditional Chinese medicine dispersion liquid containing self-assembled nanoparticles, which comprises the following steps: mixing fructus piperis longi, rhizoma corydalis, radix angelicae, ligusticum wallichii, ligusticum and indigo naturalis, crushing, sieving to obtain a traditional Chinese medicine crushed material, adding purified water, carrying out ultrasonic extraction and suction filtration to obtain a traditional Chinese medicine extracting solution, centrifuging, removing precipitate, filtering supernate by a filter membrane, and drying to obtain the traditional Chinese medicine dispersion liquid containing the self-assembled nanoparticles. And carrying out ultrafiltration centrifugation, sucking liquid in the tube, and carrying out high-speed centrifugation to obtain the traditional Chinese medicine dispersion liquid containing the self-assembled nanoparticles. The invention also provides application of the traditional Chinese medicine dispersion liquid. The prepared traditional Chinese medicine dispersion liquid containing the self-assembled nanoparticles can relieve rat migraine caused by nitroglycerin, can remarkably improve the mechanical pain threshold and the heat pain threshold of model rats and remarkably promote callback of inflammatory factors and migraine markers in brain tissues of chronic migraine rats, and is used for preparing drugs for improving migraine through nasal administration.

The invention relates to a system and method for treating neurodegenerative diseases through the activation and stimulation of stem cells using electromagnetic fields. The activated stem cells are then delivered via nasal administration to cross the blood-brain barrier and migrate to the brain, where further electromagnetic stimulation enhances the cells' effectiveness in regenerating and repairing damaged areas of the central nervous system.

The invention relates to the technical field of biological medicines, in particular to application of mesenchymal stem cell extracellular vesicles in preparation of a medicine for treating senile deafness. By utilizing the characteristics that the EVs are small in diameter and can penetrate through a biological barrier and combining abundant blood supply and innervation of the nasal cavity, the ADSCs-EVs are used for treating the senile deafness through nasal administration, the technical effect of treating the senile deafness through drugs is achieved, and the technical problems that the senile deafness is not treated through the drugs and the inner ear administration mode is invasive are solved.

Disclosed is a pharmaceutical composition to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize SARS-CoV-2 against COVID-19, wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to SARS-CoV-2 but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and / or nasal administration of the pharmaceutical composition.

Various exemplary drug delivery devices with a spinning nozzle, drug products utilizing the same, and methods of using drug delivery devices with a spinning nozzle are provided. In general, a nasal drug delivery device configured to dispense a drug therefrom includes a spinning nozzle configured to facilitate the drug's ejection into a patient's nose. The spinning nozzle is located between a drug holder containing the drug to be dispensed and an opening of the drug delivery device through which the drug exits the drug delivery device. The spinning nozzle is configured to spin during the drug's delivery as the drug travels from the drug holder and out of the drug delivery device. The spinning nozzle includes a plurality of perforations therein through which the drug as a liquid is configured to pass. The spinning of the spinning nozzle causes the drug to exit the drug delivery device as a fine mist.